Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2026)
Vivos Therapeutics' (VVOS) quarterly Change in Receivables came in at $188000.0 in Q1 2026, down 34.72% year-on-year from $288000.0 in Q1 2025, and up 134.0% on a QoQ basis from -$553000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Change in Receivables data on file, last reported at $188000.0 in Q1 2026.
- On a quarterly basis, Change in Receivables fell 34.72% year-over-year to $188000.0 in Q1 2026; TTM through Mar 2026 was $117000.0, a 39.06% decrease from a year earlier, with the FY2025 full-year figure at $217000.0, down 4.82% from the prior year.
- Change in Receivables for Q1 2026 stood at $188000.0, up from -$553000.0 in the prior quarter.
- Over the last five years, Change in Receivables for VVOS reached as high as $501000.0 in Q3 2025 and fell as low as -$553000.0 in Q4 2025.
- Historically, Change in Receivables has averaged -$21647.1 across 5 years, with a median of -$24000.0 in 2024.
- Across the five-year window, Change in Receivables slumped 2283.33% in 2024 and soared 749.15% in 2025, its largest moves.
- Year by year, Change in Receivables stood at -$409000.0 in 2022, then jumped by 93.64% to -$26000.0 in 2023, then advanced by 7.69% to -$24000.0 in 2024, then slumped by 2204.17% to -$553000.0 in 2025, then surged by 134.0% to $188000.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $188000.0 in Q1 2026, -$553000.0 in Q4 2025, and $501000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 42.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -444.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 287.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 117.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 117.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -124.60 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -141.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vivos Therapeutics | 3.62 Mn | 1.38 Mn | 3.06 Mn | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 188,000.00 |
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | -553,000.00 |
| Dec 31, 2025 | -553,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Sep 30, 2025 | 501,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Dec 31, 2023 | -26,000.00 |